BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35038360)

  • 1. Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
    Mailliez A; Pigny P; Bogart E; Keller L; D'Orazio E; Vanseymortier M; Le Deley MC; Decanter C
    Int J Cancer; 2022 Jun; 150(11):1850-1860. PubMed ID: 35038360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
    Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
    Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
    Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
    Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
    Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
    Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
    Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
    Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
    Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
    Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
    Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
    J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies.
    Lekovich J; Lobel ALS; Stewart JD; Pereira N; Kligman I; Rosenwaks Z
    J Assist Reprod Genet; 2016 May; 33(5):657-662. PubMed ID: 26943918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
    Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
    Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
    Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
    Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
    Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
    J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.